Keywords: Salix Pharma, Xifaxan, Irritable bowel syndrome, IBS, CRL, USA, FDA

Salix gets expected CRL for IBS drug Xifaxan from US FDA

Article | 09 March 2011

Print This

As was largely anticipated, the US Food and Drug Administration issued a Complete Response Letter (CRL) late Monday for Salix ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in